[ad_1]
COPENHAGEN, Denmark, Feb. 7, 2022 /PRNewswire/ — In 2021, the Novo Nordisk Foundation and Novo Holdings increased their focus on researchers and companies working with ideas and products that advance the green transition through biotechnology. Grants and investments in industrial biotechnology amounted to a total of more than €215 million in 2021.
Biotechnology – and in particular industrial biotechnology – will be one of the most crucial catalysts for the green transition, now and in the future. In order to succeed, however, it will be necessary to support the entire biotechnological ecosystem, from funding early-stage research projects to raising capital for bringing new solutions to market.
“Industrial biotech has become an important focus area for both the Novo Nordisk Foundation and our investment company, Novo Holdings. Our joint ambition is to remove the barriers for developing new biological inventions and enable them to become future solutions to environmental and climate challenges,” says Mads Krogsgaard ThomsenCEO, Novo Nordisk Foundation.
“In addition to awarding grants, we will consider how we can help researchers overcome the problems they encounter in the regulatory system for biological solutions. Unfortunately, a major barrier in launching new sustainable solutions is that regulatory impasses delay the process from the laboratory to the wider market,” he adds.
2021 has been a record year for industrial biotechnology for both the Foundation and Novo Holdings, with research grants and investments in established companies scaling new heights.
The Foundation awarded grants totalling…
Full story available on Benzinga.com
[ad_2]
Source link
